What is Pacific Biosciences of California's backlog?

Pacific Biosciences of California reported $43.8M of remaining performance obligations at 30 Sep 2026, down 10% from a year earlier and down 9% from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 0.90.

How fast does Pacific Biosciences of California's backlog turn into revenue?

Over the last twelve months Pacific Biosciences of California recognised revenue equal to about 336% of the backlog it started each quarter with.

Pacific Biosciences of California (PACB) backlog: remaining performance obligations

How much revenue Pacific Biosciences of California already has under contract, how fast it converts, and who it is with.

Data as of 7 Nov 2026.

Open the interactive Backlog view Pacific Biosciences of California competitor analysis

Pacific Biosciences of California reported $43.8M of remaining performance obligations at 30 Sep 2026, down 10% from a year earlier and down 9% from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 0.90.
Net new backlog added in the latest quarter: -$4.10M.
Over the last twelve months it turned about 336% of its opening backlog into revenue (12-month conversion).
75% of the backlog is due within the next twelve months.
Customer prepayments (contract liabilities) cover 39.5% of the backlog.
Twelve-month book-to-bill: 0.97, i.e. 0.97 of new orders for every 1 of revenue recognised.
Backlog growth minus revenue growth: -14 points — revenue is catching up with orders.
By backlog size it ranks 474th among US filers the cockpit tracks.

Pacific Biosciences of California backlog history

Remaining performance obligations at each quarter end (bars) against trailing twelve-month revenue (line).

Amounts in USD. Source: SEC XBRL filings.
Quarter end	Backlog (RPO)	TTM revenue	Coverage	Customer prepayments
30 Sep 2026	$43.8M	$161M	0.3 yrs	$17.3M
30 Jun 2026	$47.9M	$159M	0.3 yrs	$16.1M
31 Mar 2026	$46.6M	$160M	0.3 yrs	$16.3M
31 Dec 2025	$49.2M	$160M	0.3 yrs	$15.9M
30 Sep 2025	$48.7M	$155M	0.3 yrs	$16.0M
30 Jun 2025	$56.6M	$156M	0.4 yrs	$14.9M
31 Mar 2025	$58.7M	$152M	0.4 yrs	$15.2M
31 Dec 2024	$58.6M	$154M	0.4 yrs	$13.9M

Questions

What is Pacific Biosciences of California's backlog?: Pacific Biosciences of California reported $43.8M of remaining performance obligations at 30 Sep 2026, down 10% from a year earlier and down 9% from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 0.90.
How fast does Pacific Biosciences of California's backlog turn into revenue?: Over the last twelve months Pacific Biosciences of California recognised revenue equal to about 336% of the backlog it started each quarter with.

About these numbers

Remaining performance obligations (RPO) are revenue a company has contracted but not yet recognised, as reported in its SEC filings (XBRL tag RevenueRemainingPerformanceObligation). Coverage = backlog ÷ trailing twelve-month revenue. Book-to-bill = (change in backlog + revenue) ÷ revenue. Conversion = revenue recognised ÷ the backlog at the start of each quarter, summed over four quarters. Counterparty values come from company filings and releases.